Navigation Links
Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
Date:1/14/2010

STOCKHOLM, January 14 /PRNewswire/ -- Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.

"We are very excited about BioChromix Pharma as they have a novel approach that targets the cause of the disease. This is an important addition to our portfolio", says Conny Bogentoft, CEO of Karolinska Development.

"We have a clear goal - to bring our lead product candidates for Alzheimer's disease to the market. Being part of the Karolinska Development portfolio, will provided direct access to a broad network of key competencies and resources in the pharmaceutical industry which will be of great importance for us in order to succeed", says Peter Asberg, CEO of BioChromix Pharma AB.

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

Using a unique, highly cost efficient business model, the management team guides the commercialization of world class life science innovations, helping to shape the next generation pharma industry. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials. The portfolio also includes a total of 19 potential first in class products. http://www.karolinskadevelopment.com'/>"/>

SOURCE Karolinska Development AB (publ), and BioChromix AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
2. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
3. Karolinska Development Closes Fully Subscribed New Share Issue
4. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
5. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
6. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
7. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
8. Repligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreichs Ataxia Preclinical Development Program
9. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
10. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
11. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep Research Report ... "2014 Deep Research Report on Global and China ... Photo - http://photos.prnewswire.com/prnh/20140918/147058 ... and China Acetic Acid Industry" is a professional ... and Global Acetic Acid Market. The ...
(Date:9/18/2014)...  Health Enhancement Products, Inc. (OTCQB: HEPI), a ... and metabolic processes, is pleased to announce the addition of ... Nola E. Masterson , a California ... September 17, 2014. "We,re very pleased and ... states Andrew Dahl , President and CEO. "She joins ...
(Date:9/18/2014)... Texas (PRWEB) September 18, 2014 ... Chancellor John Sharp, Texas A&M Health Science Center ... U.S. Department of Health and Human Services (HHS), ... dedicated a national pandemic influenza vaccine manufacturing facility ... as an anchor for the Texas A&M Biocorridor ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Industry Report, 2014-2017" report to their offering. ... can differentiate into specialized cells and can divide (through ... can be applied to treatment of cardiovascular diseases, leukemia ... damage or lesion of liver, kidney and other parenchymal ...
Breaking Biology Technology:Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... Mass., March 11 Pressure,BioSciences, Inc. (Nasdaq: ... has joined PBI,s senior executive management team as ... nearly twenty years of experience in,sales and sales ... companies.,Mr. Potter will oversee PBI,s seven US-based, regional ...
... Lack of Flulike Side-Effects Drives Physician Prescribing of Copaxone over ... ... Resources, WALTHAM, Mass., ... advisory firms focusing on pharmaceutical and,healthcare issues, finds that Teva Pharmaceutical,s ...
... Inc.,(Nasdaq: RDEA ) today announced that Barry ... will present at Cowen and Company,s 28th Annual,Health ... Time: 4:40 p.m. Eastern Time, Location: ... Webcast:, http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=RDEA&item_id=1 ,779991, About ...
Cached Biology Technology:Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 2Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 3Matthew B. Potter Joins Pressure BioSciences, Inc. as Vice President of Sales 4Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 3Ardea to Present at Cowen and Company's 28th Annual Health Care Conference 2
(Date:9/18/2014)... Bulletin study uses tree rings to document arroyo ... in northern New Mexico, USA. By determining burial dates ... were able to precisely date arroyo sedimentary beds 30 ... with aerial imagery, LiDAR, longitudinal profiles, and repeat surveys ... are deep, oversized channels that have vertical or steeply ...
(Date:9/18/2014)... A team of researchers from McGill University and ... form of polyethylene ,microbeads, Canadian Journal of ... likely originate from cosmetics, household cleansers, or industrial ... abrasives. Owing to their small size and buoyancy, ... Microplastics are a global contaminant in the ...
(Date:9/18/2014)... DNA, tiny strands of nucleic acid that contain instructions ... genetic data, our DNA is copied into RNA molecules, ... tasks in our cells. , Several years ago, ... all other known RNAs, this molecule is circular, and ... little has been known about how they are produced. ...
Breaking Biology News(10 mins):Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Microplastic pollution discovered in St. Lawrence River sediments 2Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2
... largest mass extinction in the history of animal life occurred ... percent of marine species and 70 percent of life on ... the Earth. Multiple theories have aimed to explain the cause ... asteroid impact, massive volcanic eruptions, or a cataclysmic cascade of ...
... from Massachusetts Eye and Ear, Harvard Medical School, and ... system-on-chip (SoC) that could make possible a fully implanted ... 11at the IEEE International Solid State Circuits Conference in ... that electronically stimulates the auditory nerve to restore hearing ...
... patients who required care at Duke University Hospital during this ... vaccinated had severe cases and needed the most intensive treatment. ... treated for flu at the academic medical center from November ... only two of the 22 patients who required intensive care ...
Cached Biology News:Giant mass extinction may have been quicker than previously thought 2Giant mass extinction may have been quicker than previously thought 3Design prototype chip makes possible a fully implantable cochlear implant 2Young, unvaccinated adults account for severest flu cases 2
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Protein YIPF6 (YIP1 family member 6). [Source:Uniprot/SWISSPROT;Acc:Q96EC8] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... U.S. sourced, ideal for those ... Low hemoglobin; Endotoxin: < 1.0 ... US origin; U.S. sourced, ideal ... uncompromising quality. Low hemoglobin Endotoxin: ...
Chicken polyclonal to ytzF ( Abpromise for all tested applications). Antigen: Full length protein...
Biology Products: